PIK3CA E545K
PIK3CA E545K
|
|
PIK3CA E545K
PIK3CA E545K
|
|
cetuximab
Resistant: C3 – Early Trials
|
cetuximab
Resistant: C3 – Early Trials
|
PIK3CA E545K
PIK3CA E545K
|
Non Small Cell Lung Cancer
NSCLC
|
PIK3CA E545K
PIK3CA E545K
|
Non Small Cell Lung Cancer
NSCLC
|
osimertinib
Resistant: C3 – Early Trials
|
osimertinib
Resistant: C3 – Early Trials
|
PIK3CA E545K
PIK3CA E545K
|
Ovarian Cancer
Ovarian Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Ovarian Cancer
Ovarian Cancer
|
TAS-117
Sensitive: C3 – Early Trials
|
TAS-117
Sensitive: C3 – Early Trials
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
olaparib + durvalumab + AZD5363
Sensitive: C3 – Early Trials
|
olaparib + durvalumab + AZD5363
Sensitive: C3 – Early Trials
|
PIK3CA E545K
PIK3CA E545K
|
Gastric Cancer
Gastric Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Gastric Cancer
Gastric Cancer
|
CYH33
Sensitive: C4 – Case Studies
|
CYH33
Sensitive: C4 – Case Studies
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
CYH33
Sensitive: C4 – Case Studies
|
CYH33
Sensitive: C4 – Case Studies
|
PIK3CA E545K
PIK3CA E545K
|
Ovarian Cancer
Ovarian Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Ovarian Cancer
Ovarian Cancer
|
CYH33
Sensitive: C4 – Case Studies
|
CYH33
Sensitive: C4 – Case Studies
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
GDC-0941
Sensitive: D – Preclinical
|
GDC-0941
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
MK-2206
Sensitive: D – Preclinical
|
MK-2206
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
lapatinib
Sensitive: D – Preclinical
|
lapatinib
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine
Sensitive: D – Preclinical
|
ado-trastuzumab emtansine
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Breast Cancer
Breast Cancer
|
trastuzumab + lapatinib
Resistant: D – Preclinical
|
trastuzumab + lapatinib
Resistant: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
PIK3CA E545K
PIK3CA E545K
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
MK-2206
Sensitive: D – Preclinical
|
MK-2206
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
RTB101
Sensitive: D – Preclinical
|
RTB101
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
BMS-722782
Resistant: D – Preclinical
|
BMS-722782
Resistant: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
trametinib
Resistant: D – Preclinical
|
trametinib
Resistant: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
GDC-0941
Resistant: D – Preclinical
|
GDC-0941
Resistant: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
rigosertib
Sensitive: D – Preclinical
|
rigosertib
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA E545K
PIK3CA E545K
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
GDC-0032
Sensitive: D – Preclinical
|
GDC-0032
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
|
PIK3CA E545K
PIK3CA E545K
|
|
vemurafenib
Resistant: D – Preclinical
|
vemurafenib
Resistant: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Hepatocellular Cancer
HCC
|
PIK3CA E545K
PIK3CA E545K
|
Hepatocellular Cancer
HCC
|
alpelisib
Sensitive: D – Preclinical
|
alpelisib
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
abemaciclib + RLY-2608
Sensitive: D – Preclinical
|
abemaciclib + RLY-2608
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
palbociclib + RLY-2608
Sensitive: D – Preclinical
|
palbociclib + RLY-2608
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
PIK3CA E545K
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
RLY-2608
Resistant: D – Preclinical
|
RLY-2608
Resistant: D – Preclinical
|
